ORIC Pharmaceuticals (ORIC) Financials

$6.35 +0.40 (+6.72%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$6.60 +0.25 (+3.94%)

As of 05/23/2025 07:15 PM Eastern

Annual Income Statements for ORIC Pharmaceuticals

This table shows ORIC Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-128	-101	-89
Consolidated Net Income / (Loss)	-128	-101	-89
Net Income / (Loss) Continuing Operations	-128	-101	-89
Total Pre-Tax Income	-128	-101	-89
Total Operating Income	-143	-111	-92
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	143	111	92
Selling, General & Admin Expense	29	26	25
Research & Development Expense	114	85	67
Total Other Income / (Expense), net	15	10	2.65
Basic Earnings per Share	($1.83)	($1.96)	($2.25)
Weighted Average Basic Shares Outstanding	69.73M	51.45M	39.66M
Diluted Earnings per Share	($1.83)	($1.96)	($2.25)
Weighted Average Diluted Shares Outstanding	69.73M	51.45M	39.66M
Weighted Average Basic & Diluted Shares Outstanding	71.03M	67.38M	45.09M

This table shows ORIC Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-37	-34	-32	-25	-28	-25	-23	-24	-21	-25
Consolidated Net Income / (Loss)	-36	-35	-32	-25	-28	-25	-23	-24	-21	-25
Net Income / (Loss) Continuing Operations	-36	-35	-32	-25	-28	-25	-23	-24	-21	-25
Total Pre-Tax Income	-36	-35	-32	-25	-28	-25	-23	-24	-21	-25
Total Operating Income	-40	-38	-36	-29	-31	-29	-25	-26	-22	-26
Total Operating Expenses	40	38	36	29	31	29	25	26	22	26
Selling, General & Admin Expense	7.60	7.12	7.08	7.03	6.95	6.29	6.21	6.16	5.82	5.97
Research & Development Expense	32	31	29	22	24	22	19	20	16	20
Total Other Income / (Expense), net	3.26	3.75	4.05	3.98	3.10	3.20	2.05	1.73	1.27	0.87
Basic Earnings per Share	($0.52)	($0.49)	($0.45)	($0.37)	($0.49)	($0.44)	($0.50)	($0.53)	($0.52)	($0.63)
Weighted Average Basic Shares Outstanding	69.73M	70.54M	70.35M	67.35M	51.45M	57.40M	45.65M	45.09M	39.66M	39.58M
Diluted Earnings per Share	($0.52)	($0.49)	($0.45)	($0.37)	($0.49)	($0.44)	($0.50)	($0.53)	($0.52)	($0.63)
Weighted Average Diluted Shares Outstanding	69.73M	70.54M	70.35M	67.35M	51.45M	57.40M	45.65M	45.09M	39.66M	39.58M
Weighted Average Basic & Diluted Shares Outstanding	71.03M	70.57M	70.54M	67.42M	67.38M	54.55M	54.53M	45.09M	45.09M	39.58M

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	36	-43	-159
Net Cash From Operating Activities	-113	-86	-75
Net Cash From Continuing Operating Activities	-113	-86	-75
Net Income / (Loss) Continuing Operations	-128	-101	-89
Consolidated Net Income / (Loss)	-128	-101	-89
Depreciation Expense	1.11	1.03	0.97
Amortization Expense	-8.10	-6.17	-1.04
Non-Cash Adjustments To Reconcile Net Income	20	15	15
Changes in Operating Assets and Liabilities, net	1.97	4.90	-0.45
Net Cash From Investing Activities	22	-43	-109
Net Cash From Continuing Investing Activities	22	-43	-109
Purchase of Property, Plant & Equipment	-1.19	-0.85	-2.08
Purchase of Investments	-252	-239	-238
Sale and/or Maturity of Investments	275	197	131
Net Cash From Financing Activities	127	86	25
Net Cash From Continuing Financing Activities	127	86	25
Repayment of Debt	-0.17	-0.23	-0.40
Issuance of Common Equity	126	86	26
Other Financing Activities, net	0.63	0.06	0.08

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	15	-5.60	-6.53	33	-2.85	-77	45	-7.85	38	-20
Net Cash From Operating Activities	-28	-29	-26	-30	-24	-20	-21	-21	-15	-19
Net Cash From Continuing Operating Activities	-28	-29	-26	-30	-24	-20	-21	-21	-15	-19
Net Income / (Loss) Continuing Operations	-36	-35	-32	-25	-28	-25	-23	-24	-21	-25
Consolidated Net Income / (Loss)	-36	-35	-32	-25	-28	-25	-23	-24	-21	-25
Depreciation Expense	0.30	0.27	0.27	0.26	0.26	0.26	0.26	0.25	0.25	0.22
Amortization Expense	-1.63	-1.95	-2.30	-2.23	-2.12	-1.92	-1.26	-0.86	-0.62	-0.37
Non-Cash Adjustments To Reconcile Net Income	5.20	5.06	5.00	4.96	3.94	3.86	3.83	3.61	3.17	3.29
Changes in Operating Assets and Liabilities, net	4.38	2.39	3.37	-8.17	1.98	3.63	-1.03	0.31	2.72	2.37
Net Cash From Investing Activities	43	23	18	-62	21	-58	-19	13	28	-0.69
Net Cash From Continuing Investing Activities	43	23	18	-62	21	-58	-19	13	28	-0.69
Purchase of Property, Plant & Equipment	-0.22	-0.42	-0.33	-0.22	-0.06	-0.08	-0.41	-0.31	-0.29	-0.40
Purchase of Investments	-35	-54	-49	-114	-29	-111	-56	-43	-32	-61
Sale and/or Maturity of Investments	78	78	68	53	50	53	37	56	60	61
Net Cash From Financing Activities	0.58	0.13	0.82	125	0.45	0.03	85	0.00	25	0.00
Net Cash From Continuing Financing Activities	0.58	0.13	0.82	125	0.45	0.03	85	0.00	25	0.00
Issuance of Common Equity	0.56	-	0.52	125	0.43	-	85	0.00	25	-
Other Financing Activities, net	0.01	0.13	0.29	0.20	0.03	0.03	-	0.00	0.00	0.00

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	274	252	247
Total Current Assets	262	213	210
Cash & Equivalents	59	23	67
Short-Term Investments	197	185	139
Prepaid Expenses	6.29	4.41	4.19
Plant, Property, & Equipment, net	2.92	2.86	3.25
Total Noncurrent Assets	8.97	37	33
Long-Term Investments	0.00	27	22
Other Noncurrent Operating Assets	8.97	9.70	12
Total Liabilities & Shareholders' Equity	274	252	247
Total Liabilities	31	28	25
Total Current Liabilities	25	20	15
Accounts Payable	1.55	0.94	1.32
Accrued Expenses	23	20	14
Total Noncurrent Liabilities	6.17	7.46	9.44
Other Noncurrent Operating Liabilities	6.17	7.46	9.44
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	243	224	222
Total Preferred & Common Equity	243	224	222
Preferred Stock	0.00	0.00	0.00
Total Common Equity	243	224	222
Common Stock	806	659	558
Retained Earnings	-563	-435	-334
Accumulated Other Comprehensive Income / (Loss)	0.38	0.26	-1.29

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	302	329	351	274	292	227	238
Total Current Assets	279	295	324	232	268	193	199
Cash & Equivalents	44	50	56	26	104	59	29
Short-Term Investments	228	237	260	201	160	131	165
Prepaid Expenses	7.06	8.19	7.31	4.94	4.20	3.54	5.03
Plant, Property, & Equipment, net	3.09	2.88	2.80	3.06	3.25	3.11	3.05
Total Noncurrent Assets	20	31	24	39	20	30	36
Long-Term Investments	10.00	22	15	29	9.58	19	24
Other Noncurrent Operating Assets	9.55	9.30	9.21	10	11	11	12
Total Liabilities & Shareholders' Equity	302	329	351	274	292	227	238
Total Liabilities	28	27	22	27	23	24	23
Total Current Liabilities	21	20	15	19	15	15	13
Accounts Payable	4.25	2.31	2.99	3.74	3.19	1.93	1.53
Accrued Expenses	17	17	12	15	11	13	12
Total Noncurrent Liabilities	6.83	6.97	6.93	7.98	8.48	8.97	9.89
Other Noncurrent Operating Liabilities	6.83	6.97	6.93	7.98	8.48	8.97	9.89
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	274	302	329	247	269	203	215
Total Preferred & Common Equity	274	302	329	247	269	203	215
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	274	302	329	247	269	203	215
Common Stock	800	795	789	654	650	561	530
Retained Earnings	-526	-492	-460	-407	-381	-358	-313
Accumulated Other Comprehensive Income / (Loss)	0.72	-0.26	-0.16	-0.37	-0.57	-0.50	-1.75

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-29.31%	-26.21%	-19.88%
EBIT Growth	-28.99%	-20.72%	-16.37%
NOPAT Growth	-28.99%	-20.72%	-16.35%
Net Income Growth	-26.96%	-12.99%	-13.22%
EPS Growth	6.63%	12.89%	-8.70%
Operating Cash Flow Growth	-31.48%	-14.03%	-26.20%
Free Cash Flow Firm Growth	-35.43%	-10.21%	-27.32%
Invested Capital Growth	-17.23%	-86.50%	20.53%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-5.35%	-10.27%	-0.07%
EBIT Q/Q Growth	-6.04%	-9.17%	0.74%
NOPAT Q/Q Growth	-6.04%	-9.17%	0.74%
Net Income Q/Q Growth	-6.65%	-8.03%	2.11%
EPS Q/Q Growth	-1.67%	1.51%	2.60%
Operating Cash Flow Q/Q Growth	-3.48%	-11.65%	1.26%
Free Cash Flow Firm Q/Q Growth	-3.63%	-10.75%	1.13%
Invested Capital Q/Q Growth	-53.33%	-25.17%	-86.41%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	89.47%	90.90%	97.12%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.73%	-45.11%	-35.99%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-54.73%	-45.11%	-35.99%
Return on Equity Simple (ROE_SIMPLE)	-52.59%	-44.94%	-40.08%
Net Operating Profit after Tax (NOPAT)	-100	-78	-64
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-11.33%	-9.99%	-9.79%
Return On Investment Capital (ROIC_SIMPLE)	-41.14%	-34.61%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-143	-111	-92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-150	-116	-92
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.34	2.24	1.05
Price to Tangible Book Value (P/TBV)	2.34	2.24	1.05
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.05	-1.04	-1.03
Leverage Ratio	1.13	1.12	1.10
Compound Leverage Factor	1.01	1.02	1.07
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	7.46	7.83	3.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	10.56	10.39	13.68
Quick Ratio	10.30	10.18	13.40
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-98	-72	-66
Operating Cash Flow to CapEx	-9,483.33%	-10,092.82%	-3,616.12%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-13	-11	-5.87
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-1.89	-5.08	1.52
Enterprise Value (EV)	314	267	4.88
Market Capitalization	569	502	233
Book Value per Share	$3.45	$4.11	$5.62
Tangible Book Value per Share	$3.45	$4.11	$5.62
Total Capital	243	224	222
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-256	-235	-228
Capital Expenditures (CapEx)	1.19	0.85	2.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-16	-11
Debt-free Net Working Capital (DFNWC)	237	192	195
Net Working Capital (NWC)	237	192	195
Net Nonoperating Expense (NNE)	28	23	25
Net Nonoperating Obligations (NNO)	-256	-235	-228
Total Depreciation and Amortization (D&A)	-7.00	-5.14	-0.08
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.83)	($1.96)	($2.25)
Adjusted Weighted Average Basic Shares Outstanding	69.73M	51.45M	39.66M
Adjusted Diluted Earnings per Share	($1.83)	($1.96)	($2.25)
Adjusted Weighted Average Diluted Shares Outstanding	69.73M	51.45M	39.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	71.03M	67.38M	45.09M
Normalized Net Operating Profit after Tax (NOPAT)	-100	-78	-64
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-22.87%	-31.79%	-46.33%	-17.77%	-48.00%	-17.43%	-26.54%	-14.46%	-0.29%	-44.31%
EBIT Growth	-25.91%	-33.60%	-44.11%	-12.90%	-42.09%	-11.63%	-20.76%	-10.41%	3.01%	-39.22%
NOPAT Growth	-25.91%	-33.60%	-44.11%	-12.90%	-42.09%	-11.63%	-20.76%	-10.41%	3.01%	-39.22%
Net Income Growth	-28.16%	-35.67%	-39.31%	-4.45%	-35.89%	-2.61%	-13.10%	-3.39%	8.45%	-34.75%
EPS Growth	-6.12%	-11.36%	10.00%	30.19%	5.77%	30.16%	1.96%	10.17%	10.34%	-34.04%
Operating Cash Flow Growth	-15.59%	-46.59%	-21.19%	-46.34%	-58.33%	-1.68%	-18.95%	9.20%	5.86%	-59.12%
Free Cash Flow Firm Growth	-52.55%	-87.86%	-77.55%	-57.61%	0.47%	26.78%	16.85%	1.69%	-37.12%	-93.58%
Invested Capital Growth	-17.23%	4.30%	-24.26%	53.85%	-86.50%	-177.75%	-410.87%	-96.35%	20.53%	36.22%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-2.27%	-5.13%	-22.89%	7.01%	-9.69%	-16.74%	1.10%	-16.87%	12.97%	-25.80%
EBIT Q/Q Growth	-3.27%	-6.39%	-24.24%	7.76%	-9.57%	-14.76%	2.67%	-16.09%	13.91%	-24.15%
NOPAT Q/Q Growth	-3.27%	-6.39%	-24.24%	7.76%	-9.57%	-14.76%	2.67%	-16.09%	13.91%	-24.15%
Net Income Q/Q Growth	-5.04%	-8.14%	-27.80%	11.72%	-11.19%	-11.04%	4.18%	-14.86%	16.04%	-22.39%
EPS Q/Q Growth	-6.12%	-8.89%	-21.62%	24.49%	-11.36%	12.00%	5.66%	-1.92%	17.46%	-23.53%
Operating Cash Flow Q/Q Growth	2.58%	-12.38%	15.11%	-24.38%	-23.54%	7.09%	-2.51%	-34.57%	20.66%	-8.69%
Free Cash Flow Firm Q/Q Growth	5.10%	-13.26%	-1.79%	-39.43%	-16.87%	-7.05%	9.64%	11.95%	14.03%	-21.57%
Invested Capital Q/Q Growth	-53.33%	-36.55%	-116.91%	74.19%	-25.17%	-77.28%	19.44%	-4.33%	-86.41%	-226.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	91.75%	90.21%	88.74%	86.27%	90.14%	88.83%	91.81%	93.25%	94.25%	96.63%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.73%	-45.98%	-38.79%	-38.30%	-45.11%	-40.33%	-36.61%	-39.44%	-35.99%	-35.96%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-54.73%	-45.98%	-38.79%	-38.30%	-45.11%	-40.33%	-36.61%	-39.44%	-35.99%	-35.96%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-43.75%	-36.63%	-30.96%	0.00%	-37.68%	-34.44%	-44.33%	0.00%	-42.38%
Net Operating Profit after Tax (NOPAT)	-28	-27	-25	-20	-22	-20	-17	-18	-15	-18
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-3.51%	-2.88%	-2.32%	-1.75%	-2.73%	-2.28%	-2.13%	-2.57%	-2.11%	-2.66%
Return On Investment Capital (ROIC_SIMPLE)	-11.39%	-	-	-	-9.82%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-40	-38	-36	-29	-31	-29	-25	-26	-22	-26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-41	-40	-38	-31	-33	-30	-26	-26	-22	-26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.34	2.64	1.58	2.82	2.24	1.33	1.30	1.27	1.05	0.59
Price to Tangible Book Value (P/TBV)	2.34	2.64	1.58	2.82	2.24	1.33	1.30	1.27	1.05	0.59
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.05	-1.03	-1.02	-1.02	-1.04	-1.03	-1.01	-1.02	-1.03	-1.02
Leverage Ratio	1.13	1.11	1.09	1.09	1.12	1.11	1.09	1.10	1.10	1.09
Compound Leverage Factor	1.03	1.00	0.96	0.94	1.01	0.98	1.00	1.03	1.04	1.05
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.70	13.62	9.34	24.05	8.87	5.87	8.05	4.83	4.39	2.01
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.56	13.15	15.08	21.31	10.39	12.26	18.46	12.99	13.68	14.96
Quick Ratio	10.30	12.82	14.66	20.83	10.18	12.00	18.18	12.76	13.40	14.58
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-26	-27	-24	-24	-17	-14	-14	-15	-17	-20
Operating Cash Flow to CapEx	-12,810.05%	-6,889.23%	-7,695.20%	-13,846.79%	-42,578.95%	-25,512.99%	-5,220.99%	-6,654.19%	-5,341.12%	-4,817.96%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-13	-8.37	-6.13	-2.83	-11	-8.75	-4.94	-6.13	-5.87	-3.15
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-1.89	0.38	-1.20	3.30	-5.08	-5.60	-3.97	-3.01	1.52	1.79
Enterprise Value (EV)	314	441	168	595	267	74	76	48	4.88	-91
Market Capitalization	569	723	477	926	502	330	350	257	233	127
Book Value per Share	$3.45	$3.88	$4.49	$4.88	$4.11	$4.54	$5.96	$4.50	$5.62	$5.43
Tangible Book Value per Share	$3.45	$3.88	$4.49	$4.88	$4.11	$4.54	$5.96	$4.50	$5.62	$5.43
Total Capital	243	274	302	329	224	247	269	203	222	215
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-256	-282	-309	-331	-235	-256	-274	-209	-228	-218
Capital Expenditures (CapEx)	0.22	0.42	0.33	0.22	0.06	0.08	0.41	0.31	0.29	0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-14	-11	-7.91	-16	-14	-10	-11	-11	-8.26
Debt-free Net Working Capital (DFNWC)	237	258	275	309	192	213	254	178	195	185
Net Working Capital (NWC)	237	258	275	309	192	213	254	178	195	185
Net Nonoperating Expense (NNE)	8.61	7.74	6.75	4.72	6.33	5.40	5.45	5.97	5.36	6.84
Net Nonoperating Obligations (NNO)	-256	-282	-309	-331	-235	-256	-274	-209	-228	-218
Total Depreciation and Amortization (D&A)	-1.33	-1.68	-2.02	-1.97	-1.86	-1.67	-1.00	-0.61	-0.37	-0.15
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.52)	($0.49)	($0.45)	($0.37)	($0.49)	($0.44)	($0.50)	($0.53)	($0.52)	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	69.73M	70.54M	70.35M	67.35M	51.45M	57.40M	45.65M	45.09M	39.66M	39.58M
Adjusted Diluted Earnings per Share	($0.52)	($0.49)	($0.45)	($0.37)	($0.49)	($0.44)	($0.50)	($0.53)	($0.52)	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	69.73M	70.54M	70.35M	67.35M	51.45M	57.40M	45.65M	45.09M	39.66M	39.58M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	71.03M	70.57M	70.54M	67.42M	67.38M	54.55M	54.53M	45.09M	45.09M	39.58M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-27	-25	-20	-22	-20	-17	-18	-15	-18
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

When does ORIC Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, ORIC Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has ORIC Pharmaceuticals' net income changed over the last 2 years?

ORIC Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$127.85 million in 2024, rising from -$89.12 million in 2022. The previous period was -$100.70 million in 2023. See where experts think ORIC Pharmaceuticals is headed by visiting ORIC Pharmaceuticals' forecast page.

What is ORIC Pharmaceuticals's operating income?

ORIC Pharmaceuticals's total operating income in 2024 was -$142.90 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $142.90 million

How has ORIC Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does ORIC Pharmaceuticals have?

ORIC Pharmaceuticals' total liabilities were at $31.02 million at the end of 2024, a 11.1% increase from 2023, and a 24.9% increase since 2022.

How much cash does ORIC Pharmaceuticals have?

In the past 2 years, ORIC Pharmaceuticals' cash and equivalents has ranged from $23.38 million in 2023 to $66.84 million in 2022, and is currently $59.41 million as of their latest financial filing in 2024.

How has ORIC Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' book value per share changed from 5.62 in 2022 to 3.45 in 2024, a change of -38.7%.

Related Companies

This page (NASDAQ:ORIC) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ORIC Pharmaceuticals (ORIC) Financials

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ORIC Pharmaceuticals (ORIC) Financials

Annual Income Statements for ORIC Pharmaceuticals

Quarterly Income Statements for ORIC Pharmaceuticals

Annual Cash Flow Statements for ORIC Pharmaceuticals

Quarterly Cash Flow Statements for ORIC Pharmaceuticals

Annual Balance Sheets for ORIC Pharmaceuticals

Quarterly Balance Sheets for ORIC Pharmaceuticals

Annual Metrics And Ratios for ORIC Pharmaceuticals

Quarterly Metrics And Ratios for ORIC Pharmaceuticals

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools